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ABSTRACT 
Fungal peritonitis in the peritoneal dialysis population is difficult to diagnose promptly due to the 
inherently slow cultivation-based methods currently required for identification of peritonitis 
pathogens. Because of the moderate risk for severe complications, the need for rapid diagnostics 
is considerable. One possible solution to this unmet need is the T2Candida Panel, a new technology 
designed to detect the most common pathogenic Candida spp. directly from whole blood 
specimens in as little as a few hours. We hypothesized that this technology could be applied to the 
detection of Candida in peritoneal dialysate, a matrix not currently approved by the Food and Drug 
Administration for testing by this system. Remnant dialysate samples from three healthy (non-
infected) pediatric peritoneal dialysis patients were spiked with Candida glabrata, serially diluted, 
and tested in triplicate with unaltered dialysate specimens. The assay detected C. glabrata in 100% 
of spiked dialysate samples across the full spectrum of dilutions tested, and no assay inhibition or 
cross-reactivity was noted. These findings suggest one of possibly more applications of this 
technology. The positive clinical implications of this test will continue to be realized as its use is 
validated in peritoneal dialysate and other patient specimen types.  
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INTRODUCTION 
 Peritoneal dialysis is often the preferred form of renal replacement therapy for pediatric 
patients with end-stage renal disease (ESRD) (1).   One complication of peritoneal dialysis is 
severe and potentially life-threatening peritonitis (1, 2).  
 Fungal peritonitis in the peritoneal dialysis population is rare; however, it is associated 
with high morbidity and mortality (2, 3).  The most commonly implicated fungal pathogens in 
peritonitis include Candida albicans, Candida parapsilosis, and Candida glabrata (3). The 
management of fungal peritonitis is unique because prompt removal of the peritoneal dialysis 
catheter is required in addition to initiation of antifungal treatment (4). Currently, the gold standard 
for the diagnosis of fungal peritonitis is fungal culture, a slow process that can take up to 24-48 
hours, resulting in significant diagnostic and therapeutic delays. 
 A novel magnetic resonance-based technology has emerged for the detection of the most 
common causes of candidemia, including C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, 
and C. krusei. The T2Dx system (T2 Biosystems, Lexington, MA) is comprised of the T2Dx 
Instrument and a U.S. Food and Drug Administration (FDA)-cleared candidemia detection panel, 
the T2Candida Panel. This technology uses T2 magnetic resonance to detect as little as one to three 
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colony forming units per milliliter (CFU ml-1) of the aforementioned Candida spp (5).  Another 
attractive feature of this system is that it tests EDTA-anticoagulated whole blood specimens, 
obviating the need for cultivation prior to sample analysis (6). When used in the appropriate 
context, the T2 system has been shown to reduce the time-to-detection of candidemia to 
approximately 3 hours (5).  
 We hypothesized that that the high sensitivity of this system coupled with its rapid 
detection time would make it an attractive candidate for testing additional sample matrices, 
including peritoneal dialysate.  As such, this tool could help improve patient survival, lessen the 
effects of fungal peritonitis on the peritoneal membrane, and curb the use of unwarranted 
antimicrobial therapy (4, 7, 8). To that end, we challenged the ability of the T2Candida Panel to 
detect C. glabrata in samples of peritoneal dialysate.  
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METHODS 
Ethics statement. This study was approved by the IRB of the IU School of Medicine, Indianapolis, 
IN. All samples in this study were de-identified to protect the privacy of the patients.  Informed 
consent was not required. 
 
There were three main steps to conducting this study: (1) Retrieving dialysate samples from 
otherwise healthy (non-infected) patients; (2) Spiking the samples with C. glabrata in the 
laboratory; (3) Analyzing the specimens on with the T2Candida Panel.  See Figure 1. 
 
Dialysate fluid procurement and testing. Samples were collected from peritoneal dialysis 
patients randomly during their monthly routine clinic visit.  They brought their dialysate from 
home for their routine Kt/V calculation.  Two 60-mL syringes of this remnant dialysate from each 
patient were submitted for experimentation.   Remnant peritoneal dialysates from three pediatric 
patients were used for all analyses described herein. Dialysate compositions of 1.5% and 2.5% 
dextrose, and a combination of 1.5% and 2.5% dextrose, were selected for T2 analysis and 
manipulation to assess for interference over a range of dextrose concentrations.  
   
Preparation of contrived dialysates. Prior to experimental manipulation, dialysates were stored 
at 4°C.  All dialysate specimens were spiked and analyzed by the T2Dx instrument within 48 h of 
sample collection (range, 11:15 h – 41:44 h; mean, 29:09 h).  Suspensions of Candida glabrata 
ATCC MYA-2950 were prepared using the remnant peritoneal dialysate fluid described above. 
Briefly, C. glabrata was grown on Sabouraud dextrose agar (SDA) and colonies were transferred 
to sterile normal saline aliquots. The turbidity of each suspension was adjusted to the approximate 
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density of a 0.5 McFarland standard.  10-2, 10-4 and 10-6 dilutions, prepared using dialysate, of 0.5 
MF C. glabrata solution were subsequently created for T2Candida Panel analysis.  C. glabrata 
concentrations were confirmed by colony counts from 0.1 mL of dialysate solutions incubated on 
SDA plates.  
 
T2Candida Panel analysis.   Briefly, 10-2 (3x104CFU/mL), 10-4 (300CFU/mL), and 10-6 
(3CFU/mL) standard dilutions, each in triplicate, of C. glabrata-spiked dialysate were transferred 
to 4-ml BD Vacutainer tubes (BD, Franklin Lakes, NJ) containing EDTA and were tested using 
the T2Candida Panel according to the manufacturer’s instructions for whole blood analysis. 
Undiluted, non-spiked dialysate fluids were tested concurrently as negative controls.  The time 
from standard dilution preparation to automated analysis was less than one hour.   
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RESULTS 
 Assay results were released from the T2Dx system qualitatively in three categories: C. 
albicans/C. tropicalis, C. parapsilosis, and C. glabrata/C. krusei.  All assay results were valid with 
no interference identified. There was 100% concordance between spiked specimens and negative 
controls with test results, and therefore the expected results were obtained. See Table 1 for 
complete assay results including glucose concentrations of dialysates..  
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DISCUSSION 
 To our knowledge, this is the first study of its kind.  Although limited to three dialysate 
samples, we reproducibly demonstrated that the T2Candida Panel was able to detect C. glabrata 
in spiked peritoneal dialysate samples.  However, the results in this study should be considered 
preliminary.   
C. glabrata alone was chosen for this pilot study due to a limited number of testing kits 
and uniqueness among Candida species for not producing pseudohyphae, which made organism 
quantification more accurate.  We also chose to use remnant dialysate to simulate, as best as 
possible, the sample matrices that would be obtained directly from patients with fungal peritonitis.  
 This test has the potential to have profound clinical relevance in patients with suspected 
fungal peritonitis. Early detection of fungal pathogens allowing for prompt treatment may 
improve patient survival.  Other potential benefits include narrowing of antimicrobial coverage 
to mitigate toxicity and untoward side effects as well as prevent the spread of antimicrobial 
resistance. For instance, intraperitoneal cefepime administration has been rarely associated with 
neurotoxicity and IP vancomycin has been associated with significant antimicrobial resistance 
(4). Thus, patients with atypical or severe presentations of peritonitis could benefit from early 
detection of a causative organism to improve morbidity and mortality the infection.  
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LEGEND 
Figure 1: Study Protocol  
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TABLE 1 T2Candida Dialysate Assay Results 14 
 15 
Dialysate 
dextrose 
concentration 
Actual measured 
glucose (mg/dL) Concentration of C. glabrata 
(CFU mL-1) 
Number of 
specimens 
C. albicans/ C. 
tropicalis C. parapsilosis 
C. glabrata/ 
C. krusei Syringe  
1 
Syringe  
2 
1.5% 1050 1059 
> 1000 3 Negative (3) Negative (3) Positive (3) 
380 3 Negative (3) Negative (3) Positive (3) 
3.3 3 Negative (3) Negative (3) Positive (3) 
0 (neg ctrl) 2 Negative (2) Negative (2) Negative (2) 
1.5% + 2.5% 1120 1129 
> 1000 3 Negative (3) Negative (3) Positive (3) 
470 3 Negative (3) Negative (3) Positive (3) 
3.3 3 Negative (3) Negative (3) Positive (3) 
0 (neg ctrl) 2 Negative (2) Negative (2) Negative (2) 
2.5% 1757 1744 
> 1000 3 Negative (3) Negative (3) Positive (3) 
453 3 Negative (3) Negative (3) Positive (3) 
4.4 3 Negative (3) Negative (3) Positive (3) 
0 (neg ctrl) 2 Negative (2) Negative (2) Negative (2) 
(2) 60mL syringes of remnant
dialysate from  routine Kt/V collection 
obtained using sterile technique  
0.5 MF C. glabrata in quality 
controlled sterile normal saline (SNS) 
Dilutions of 10-2, 10-4, & 10-6 
0.5 MF of C. glabrata 
solution made with dialysate 
solution as diluent 
Specimens analyzed using T2MR 
T2Candida Panel in Triplicate 
Glucose concentration 
measured 
0.1 mL plated and 
incubated - colony count
Dialysate & SNS analyzed using 
T2MR T2Candida Panel (Neg Ctrl)
